Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 20,930 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-treatment Clear all

Conditions: Neoplasms
Interventions: GSK3901961, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more

Conditions: Avoidant Restrictive Food Intake Disorder
Interventions: ARFID-PTP; Behavioral
Lead sponsor: University at Albany; Other
Eligibility: 5 Years to 12 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Albany, New York

Conditions: Cystic Fibrosis
Interventions: BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire, CF Management Questionnaire, Food Frequency Questionnaire; Diagnostic Test · Other · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 23
States / cities: Tucson, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 19 more

Conditions: Refractive Errors, Astigmatism
Interventions: SynergEyes A2 Hybrid Contact Lens; Device
Lead sponsor: SynergEyes, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Campbell, California • Carlsbad, California • Encino, California + 7 more

Conditions: Mechanical Ventilation, Critical Illness
Interventions: Dexmedetomidine, Propofol, Fentanyl, Midazolam, Physical and Occupational Therapy; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spasms, Infantile
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 1 more

Conditions: Cutaneous Lupus Erythematosus (CLE)
Interventions: Lenalidomide; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: K8; Drug
Lead sponsor: Michelle Abou-Jaoude; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Non-Small Cell Lung Cancer
Interventions: MEDI4736, PLACEBO; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 60
States / cities: Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more

Conditions: High Grade Serous Carcinoma
Interventions: Olaparib Pill, AZD6738; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Chronic Knee Pain
Interventions: Photobiomodulation therapy (PBM) device, Sham PBM device; Device
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Breast Cancer
Interventions: Radiomics on MRI, microbubble CEUS Contrast Enhanced Ultrasound (CEUS); Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: SRP, Minocycline HCl Microspheres, Biomarkers
Interventions: Measurement of Biomarkers; Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Antiphospholipid (aPL)-Positive
Interventions: Study Drug- ALXN1007; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: New York, New York • Galveston, Texas • Fairfax, Virginia

Conditions: Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1
Interventions: Device: EVOS Lumbar Interbody System (EVOS-HA); Device
Lead sponsor: Invibio Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Charlotte, North Carolina • Philadelphia, Pennsylvania

Conditions: Lung Cancer, Pleural Effusion
Interventions: ZD6474; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiac Rehabilitation
Interventions: Case Management; Behavioral
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more

Conditions: Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis, Knee Arthropathy
Interventions: Dorsal Root Ganglion Stimulation; Device
Lead sponsor: Kenneth B Chapman; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Malignancies
Interventions: CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod, poly-ICLC; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 7
States / cities: New Haven, Connecticut • Miami Beach, Florida • Detroit, Michigan + 3 more

Conditions: Heart Failure
Interventions: Remote Dielectric Sensing (ReDS) Wearable System; Device
Lead sponsor: Sensible Medical Innovations Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 41
States / cities: Birmingham, Alabama • Hollywood, California • La Jolla, California + 34 more

Conditions: Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions: EORTC QLQ-C30 questionnaire, QLQ-OGS25 questionnaire; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
Interventions: Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy, Research blood draw; Device · Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

A Two-Session Exposure Treatment and Parent Training for ARFID

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis (EPIC-KO)

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial

A Study of LY3484356 in Healthy Female Participants

Systemic Markers of Inflammation: 9- and 12-Month Follow-Up Post Non-Surgical Periodontal Therapy

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages in the Lumbar Spine

Malignant Pleural Effusion With ZD6474

Early Case Management on Recovery From a Cardiac Event in Women

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Dorsal Root Ganglion Stimulation for the Treatment of Arthritic Knee Pain

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients

Registry for Esophageal and Gastroesophageal Junction Cancer

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma